Van Heerden J, Hendricks M, Geel J, et al. - Since the poor outcome is reported in low- and middle-income countries, researchers by analyzing data from 390 patients [median age was 39.9 months (range, 0–201 months)] conducted this multi-institutional retrospective study to determine outcome data for neuroblastoma in sub-Saharan Africa between 2000 and 2014. To determine two-year survival rates and to identify prognostic factors, Kaplan–Meier curves and Cox regression models were used. OPEC/OJEC (44.8%), St Jude NB84 protocol (28.96%), and Rapid COJEC (22.17%) were the main chemotherapy regimens. Data reported that the 2-year overall survival (OS) for the whole cohort was 37.6%: 94.1%, 81.6%, and 66.7%, respectively, for the very-low-risk, low-risk, and intermediate-risk groups and 27.6% for the high-risk group. In comparison with MYCN-amplified patients at 37.3%, MYCN-nonamplified patients had a superior two-year OS of 51.3%. According to findings, the limited disease had an OS similar to high-income countries but a poor OS was found in advanced disease. South Africa should concentrate on early diagnosis and execution of equitable access to treatment national protocol.